Recent studies presented at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK have identified multiple exciting new treatment combinations for multiple myeloma. In this interview, Alberto Rocci, MD from Central Manchester University Hospital, Manchester, UK highlights the benefits these could have on patient survival, their tolerability and the potential created for tailoring treatment to the individual. Moving forward, Dr Rocci discusses improving the accessibility and funding of these drugs. This content has been supported by Napp Pharmaceuticals through an unrestricted educational grant to Magdalen Medical Publishing. The company has had no influence on the production of the content.
